Physician profile
Kendra Bowles
NPI 1598536575
$796.41
in general payments reported to CMS, 2019-2025
22 companies · $796 in 2025
The $796 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $94.36 | 2025 | Rexulti, Abilify Asimtufii |
| Astrazeneca Pharmaceuticals Lp | $93.87 | 2025 | Breztri, Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.06 | 2025 | Caplyta |
| Abbvie INC. | $64.96 | 2025 | |
| Neurocrine Biosciences, INC. | $62.97 | 2025 | |
| Alkermes, INC. | $45.72 | 2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $45.59 | 2025 | Austedo Xr, Uzedy |
| Aimmune Therapeutics, INC. | $42.95 | 2025 | Zenpep |
| Astellas Pharma US INC | $36.31 | 2025 | Veozah |
| Globus Medical, INC. | $30.88 | 2025 | Senza |
| Pfizer INC. | $27.30 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.70 | 2025 | Xifaxan |
| Phadia US INC. | $18.36 | 2025 | Immunocap |
| Boston Scientific Corporation | $16.99 | 2025 | Watchman Flx |
| Abbott Laboratories | $16.35 | 2025 | Freestyle Libre |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $14.41 | 2025 | Yupelri |
| Lundbeck LLC | $14.41 | 2025 | Rexulti |
| Exact Sciences Corporation | $14.07 | 2025 | The Cologuard Plus Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $14.05 | 2025 | Cobenfy |
| Bayer Healthcare Pharmaceuticals INC. | $13.95 | 2025 | |
| Merck Sharp & Dohme LLC | $13.92 | 2025 | Vaxneuvance, Capvaxive, Enflonsia |
| Phathom Pharmaceuticals, INC. | $10.23 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendra Bowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.